Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(11):790-792; doi:10.1093/jnci/94.11.790
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Arnold, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arnold, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 11, 790-792, June 5, 2002
© 2002 Oxford University Press

NEWS

Collaboration to Play Key Role in NCI’s Future, Director Says

Interview by Katherine Arnold

Andrew von Eschenbach, M.D., took the helm as the director of the National Cancer Institute earlier this year. He was previously at the University of Texas M. D. Anderson Cancer Center in Houston, where he headed the Genitourinary Cancer Center and the Prostate Cancer Research Program. Von Eschenbach is also a member of the National Dialogue on Cancer, an independent forum of cancer experts from several key national organizations.


Figure Removed (Available Only in the Full Text)
View larger version (113K):
[in this window]
[in a new window]
  		Dr. von Eschenbach

 
Von Eschenbach discussed with the Journal his first few months as director and his plans for the future.

How have your first few months as NCI director been?

Exhilarating. I came with the expectation that I would spend the first quarter listening, learning, and hopefully understanding the organization and the people within it. The fact that I had not been in the institution—I spent 25 years at a cancer center—is a two-sided coin. I bring different perspectives, but at the same time there’s much that I needed . . . [Full Text of this Article]

What types of things are you looking at changing?

What is the role of NCI in collaborations like the National Dialogue on Cancer and in partnering with other cancer organizations?

Do you see opportunities to partner with industry?

Our understanding of cancer has shifted in the last 25 years. So, too, must the research. Is NCI set up to change focus to accommodate the changing understanding of cancer?

Shortly after taking over as director, you were called upon to testify before Congress on mammography. How do we continue to evaluate new screening tests?

The Bush administration has taken some firm stands on medical research. How does that affect NCI?

Now that you have been here for a few months and now that you’re immersed, do you have a different understanding and respect for what it’s going to take to win the war on cancer?

How will we get the next Gleevec?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
N. Tolliday, P. A. Clemons, P. Ferraiolo, A. N. Koehler, T. A. Lewis, X. Li, S. L. Schreiber, D. S. Gerhard, and S. Eliasof
Small Molecules, Big Players: the National Cancer Institute's Initiative for Chemical Genetics.
Cancer Res., September 15, 2006; 66(18): 8935 - 8942.
[Abstract] [Full Text] [PDF]